newsfilter
← Latest News
GlobeNewswire·

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in